Navigation Links
Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer
Date:3/25/2008

SAN DIEGO, March 25 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced the appointment of Anthony "Tony" W. Fox as part-time Chief Medical Officer to oversee the recently initiated Phase 2 clinical trial of CTS-1027 in Hepatitis C virus-infected patients as well as assisting in the development of the longer-term clinical development plans.

Tony is a pharmaceutical physician with more than 20 years in the industry. Previous industrial positions have been at Procter and Gamble, Glaxo Inc. (Imitrex (R), Ultiva(R), Amerge(R)), and with small companies. Formerly, Tony was President of the whole of EBD Group, and continues now as President of EBD Consulting Inc., (Carlsbad, CA, and Munich, Germany). Among his current professional affiliations are the American College of Clinical Pharmacology, the American Society of Pharmacology and Experimental Therapeutics, and the Society of Apothecaries of London. He is a Fellow of the Institute of Biology and the Royal College of Physicians, as well as of the latter's Faculty of Pharmaceutical Medicine. Tony's numerous publications span industrial, pharmacological, regulatory, and experimental medicine areas. He co-edits "Principles and Practice of Pharmaceutical Medicine" (John Wiley and Son, second edition), which is a major international textbook in its field.

"Tony fills a critical position at Conatus," said Steven J. Mento, Ph.D., President and CEO, of Conatus. "He brings significant scientific and management experience and will be of strategic value as Conatus moves forward with the development of drug candidates to treat diseases such as hepatitis where abnormal inflammation plays a key role."

"This was an opportunity to focus on translating a well-known biological mechanism, with a well-characterized phase 2 compound, into a truly innovative area of medicine. It was also an invitation to join a team whom I already knew to be really sound, and has already achieved hard endpoints," said Dr. Fox.

Conatus Pharmaceuticals Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease. Chronic liver disease affects millions of people worldwide and can be caused by many different conditions or "insults" to the liver including viral infection, obesity, chronic alcohol abuse or autoimmune diseases. Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the successful sale of Idun to Pfizer. For additional information, please visit http://www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and Related Disorders (CARD) Portland ... autism spectrum disorder (ASD) and other developmental disabilities. The group, which is being launched ... other caregivers the opportunity to share stories and advice, seek help, and continue their ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... California, will be included in the 2016 “Guide to America’s Top Plastic Surgeons” ... on the amalgamation of their education, experience, and professional associations. , One ...
(Date:12/2/2016)... ... 2016 , ... Universal Medical Systems, Inc. (UMS) the world's ... to offer robotic imaging to veterinary medicine is sponsoring the appearance of Millennia, ... American Association of Equine Practitioners 62nd Annual Convention from December 4-6, 2016 in ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... today that it has raised $6.0 million in an initial round of funding. ... conviction that patients and their caregivers can receive far better care through the ...
(Date:11/30/2016)... ... November 30, 2016 , ... The Fertility Centers ... as a Cigna Infertility Center of Excellence. The Cigna Center of Excellence recognizes ... an honor to be designated a Cigna Infertility Center of Excellence," said Fertility ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... WOONSOCKET, R.I. , Dec. 2, 2016 ... hold its annual Analyst Day in New York City on Thursday, December ... the CVS Health leadership team will provide an in-depth ... and enhance shareholder value. The company will also discuss ... audio and video webcast of the event will be ...
(Date:12/2/2016)... Lianluo Smart Limited (Nasdaq: ... develops, markets and sells medical devices and wearable ... and international markets, recently attended the 2016 ... Progress Forum, co-hosted by the Institute of Interventional ... Guangdong Provincial People,s Hospital and Cardiology Department of ...
(Date:12/2/2016)... On Thursday, the NASDAQ Composite ended the trading ... edged 0.36% higher, to finish at 19,191.93; and the S&P ... as six out of nine sectors ended the day in ... Services equities: Myriad Genetics Inc. (NASDAQ: MYGN ), ... Inc. (NASDAQ: INCR ), and La Quinta Holdings ...
Breaking Medicine Technology: